The GLP-1 compounding market changed dramatically in 2025, and practices running medical weight loss programs need to understand what happened, where things stand now, and how to build programs that can adapt as regulations continue to evolve.
This guide covers the key regulatory changes, what they mean for your practice, and practical strategies for running a sustainable GLP-1 weight loss program in 2026.
Timeline: What Happened
The Shortage Era (2022-2025)
The GLP-1 story starts with unprecedented patient demand. As semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) gained mainstream attention for weight loss, demand far exceeded supply from the brand manufacturers Novo Nordisk and Eli Lilly.
The FDA added semaglutide to the drug shortage list, which triggered an important legal exception: under Section 503B of the Federal Food, Drug, and Cosmetic Act, outsourcing facilities can compound copies of commercially available drugs during a declared shortage.
This opened the door for compounding pharmacies to produce semaglutide and tirzepatide, creating a secondary market of compounded GLP-1 medications. Thousands of medical practices built weight loss programs around compounded semaglutide, often at significantly lower patient cost than brand-name alternatives.
February 2025: The Shortage Ends
In February 2025, the FDA announced that the semaglutide shortage had resolved. This was the pivotal moment for compounding practices because the shortage resolution removed the legal basis for 503B facilities to compound copies of brand-name semaglutide.
The FDA established a wind-down period:
- 503B outsourcing facilities received a 60-day wind-down period to stop distributing compounded semaglutide
- 503A pharmacies were subject to separate enforcement considerations, with the FDA acknowledging that 503A compounding operates under different legal authority
Legal Challenges
The end of the shortage did not go unchallenged. Compounding pharmacies and industry groups filed legal challenges arguing that the FDA’s shortage resolution was premature, that patient access would be harmed, and that specific compounding pathways remained legally available even outside the shortage exception.
Several court actions resulted in temporary restraining orders and preliminary injunctions that delayed or modified FDA enforcement in specific cases. The legal environment has continued to evolve through 2025 and into 2026.
Current Status (2026)
As of mid-2026, the situation is:
- 503B compounding of semaglutide copies under the shortage exception has largely ended, though some legal challenges continue in specific jurisdictions
- 503A pharmacy compounding operates under different authority, and some 503A pharmacies continue to compound semaglutide under provisions that do not rely on the shortage exception
- Tirzepatide has followed its own regulatory timeline, with its shortage status tracked separately by the FDA
- Brand-name prescribing through Novo Nordisk and Eli Lilly remains available, though patient cost is significantly higher than compounded alternatives were
- Congressional attention to compounding access remains active, with proposals to clarify or expand compounding authority
Understanding the Regulatory Pathways
503A: Patient-Specific Compounding
503A pharmacies compound medications based on individual patient-specific prescriptions. Their authority comes from Section 503A of the FD&C Act and is primarily regulated by state pharmacy boards.
Key points for GLP-1 compounding:
- Not dependent on shortage declarations. 503A compounding authority is not tied to whether a drug is in shortage. The legal framework is different from 503B.
- “Essentially a copy” provisions. 503A pharmacies generally cannot compound drugs that are “essentially a copy” of a commercially available product unless they meet specific conditions, including clinical differentiation documented by the prescriber.
- State-level variation. State pharmacy boards interpret and enforce compounding regulations differently. What is permitted in one state may not be in another.
- Prescriber relationship required. 503A compounding requires a valid patient-specific prescription from a licensed prescriber with a documented patient relationship.
503B: Outsourcing Facilities
503B outsourcing facilities are FDA-registered and can compound in larger batches, but their ability to compound copies of commercially available drugs is limited:
- Shortage exception removed for semaglutide. Once the shortage ended, 503B facilities lost the legal basis to compound copies of brand-name semaglutide under this specific provision.
- Other pathways may exist. 503B facilities can compound drugs that appear on the FDA’s bulk drug substances list and are not essentially a copy of a commercially available drug. Whether specific GLP-1 formulations qualify depends on the formulation details and FDA interpretation.
- FDA inspection and oversight. 503B facilities face more rigorous federal oversight than 503A pharmacies, including FDA inspections and cGMP requirements.
Brand-Name Prescribing
Prescribing brand-name Ozempic, Wegovy, Mounjaro, or Zepbound remains straightforward:
- No compounding regulatory complexity. You are prescribing an FDA-approved medication through standard pharmacy channels.
- Higher patient cost. Without insurance coverage, brand-name GLP-1 medications cost significantly more than compounded alternatives. Manufacturer savings programs exist but have eligibility requirements.
- Supply stability. Brand-name supply has largely stabilized since the acute shortage period, though availability can vary by dosage strength and region.
How Practices Should Adapt
The practices that are thriving in 2026 are the ones that built flexible programs rather than depending on a single compounding pathway.
Strategy 1: Multi-Pharmacy Relationships
Do not rely on a single pharmacy partner. Build relationships with multiple pharmacies across different regulatory pathways:
- A 503A pharmacy that has a defensible pathway for GLP-1 compounding
- A 503B facility for medications where they have clear authority (peptides, hormones, non-GLP-1 compounds)
- Brand-name prescribing capability as a fallback or premium option
This gives you supply chain resilience regardless of how the regulatory environment evolves. See our guide to choosing pharmacy partners for a detailed evaluation framework.
Strategy 2: Diversify Beyond GLP-1
The GLP-1 compounding restrictions reinforced an important lesson: programs dependent on a single therapy type are vulnerable. Practices that diversified into adjacent programs absorbed the GLP-1 changes more easily.
Peptide therapy is the most natural complement to GLP-1 weight loss. With the expected FDA peptide reclassification, peptide therapy programs are poised for growth. The patient demographic overlaps significantly with GLP-1 patients.
Testosterone replacement therapy (TRT) and hormone replacement therapy (HRT) serve different patient populations but share the same operational infrastructure: patient intake, clinical review, compounding pharmacy fulfillment, and automated follow-up.
Running multiple programs from a single platform means the infrastructure investment for your first program pays dividends across every additional program you add.
Strategy 3: Build on a Flexible Platform
Your technology platform should make it easy to adapt as regulations change:
- Multi-pharmacy routing so you can switch pharmacy sources without changing your workflow
- Program-agnostic infrastructure that supports GLP-1, peptides, TRT, and HRT from the same system
- Intake and prescribing flexibility so adding a new therapy does not require building new infrastructure
- Pharmacy integration that handles the routing and fulfillment complexity for you
Practices that built custom workflows tied to a single pharmacy or therapy type are the ones scrambling to adapt. Practices on flexible platforms simply adjust their pharmacy routing and continue operating.
Strategy 4: Stay Informed
The regulatory environment is not static. Stay current on:
- FDA enforcement actions and guidance related to compounding
- Court decisions that may expand or restrict compounding authority
- State pharmacy board updates for states where you practice or have patients
- Industry group communications from organizations like the Alliance for Pharmacy Compounding and relevant medical societies
Your pharmacy partners should be a source of regulatory intelligence. Good pharmacy partners proactively communicate about changes that affect your prescribing.
What This Means for Your Weight Loss Program
If you are running a GLP-1 weight loss program or considering starting one, here is the practical takeaway:
GLP-1 weight loss programs are still viable and profitable. The regulatory changes affected the compounding supply chain, not the clinical viability or patient demand for medical weight loss. Patients still want medically supervised weight loss programs. The question is how you source the medication and structure the program.
Build for flexibility. Design your program to work across multiple GLP-1 sources: compounded (where legally available), brand-name, and potentially new entrants as the market evolves.
Complement with adjacent programs. Peptide therapy, TRT, and HRT share infrastructure and patient demographics with GLP-1 weight loss. Offering multiple programs reduces your dependence on any single therapy.
Use technology to manage complexity. Multi-pharmacy routing, automated patient follow-up, and integrated prescribing workflows make it possible to run a flexible program without proportionally increasing administrative overhead.
How Karpa Health Helps
Karpa Health is built for exactly this kind of regulatory flexibility. The platform supports:
- GLP-1 weight loss programs with multi-pharmacy routing to integrated pharmacy partners
- Peptide therapy programs ready for the expected Category 1 reclassification
- TRT and HRT programs from the same platform
- AI-powered clinical review that reduces physician time per patient regardless of the therapy type
- Automated patient follow-up that keeps patients on protocol across all programs
The platform adapts as regulations change. When a pharmacy pathway opens or closes, you adjust your routing without rebuilding your program infrastructure.
Book a demo to see how Karpa Health supports flexible GLP-1 and multi-program practices.
Book a call with Karpa Health if you want help structuring the right program.
